Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

GL-701 Genelabs.

¹Norman Consulting Burnham, Bucks, UK. peter.norman2@btinternet.com

Current Opinion in Investigational Drugs (London, England : 2000)

|January 31, 2002

Summary

This summary is machine-generated.

Genelabs is developing GL-701 (prasterone), an oral dehydroepiandrosterone (DHEA) therapy, for systemic lupus erythematosus (SLE). The FDA granted GL-701 Priority Review and Fast Track designations, supporting its expedited development and review.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Working with Insulin, Carbohydrates, Ketones and Exercise to Manage Diabetes (WICKED): evaluation of a self-management course for young people with Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2019

Same author

Experiences of self-management among young adults with Type 1 diabetes in the context of a structured education programme: a qualitative study.

Diabetic medicine : a journal of the British Diabetic Association·2018

Same author

Optical absorption and magnetic circular dichroism spectra of thiouracils: a quantum mechanical study in solution.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2017

Same author

Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.

BMJ open·2016

Same author

The importance of mindfulness in psychosocial distress and quality of life in dermatology patients.

The British journal of dermatology·2016

Same author

Patient and hospital determinants of primary percutaneous coronary intervention in England, 2003-2013.

Heart (British Cardiac Society)·2016

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Pharmacology
Immunology
Endocrinology

Background:

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant unmet medical needs.
Dehydroepiandrosterone (DHEA), also known as prasterone, is an endogenous steroid hormone with immunomodulatory properties.
Current SLE treatments often have limitations in efficacy and tolerability.

Purpose of the Study:

To evaluate the efficacy and safety of GL-701 (prasterone) as a potential treatment for systemic lupus erythematosus (SLE).
To assess the potential of GL-701 to reduce corticosteroid dosage in SLE patients.

Main Methods:

Genelabs submitted a rolling New Drug Application (NDA) to the US FDA for GL-701.
The NDA submission included comprehensive clinical, statistical, and human pharmacokinetic data.

Related Experiment Videos

Two Phase III clinical trials in women with SLE were conducted to gather efficacy and safety data.

Main Results:

GL-701 (prasterone) received Fast Track and Orphan Drug designations from the US FDA, facilitating expedited development and review.
The FDA granted Priority Review designation for the GL-701 NDA.
The drug was patented for its use in reducing corticosteroid dosage in lupus patients.

Conclusions:

GL-701 (prasterone) represents a promising therapeutic candidate for systemic lupus erythematosus.
Regulatory designations suggest potential for accelerated market entry and availability to patients.
Further clinical evaluation and regulatory review are ongoing to determine the full therapeutic potential of GL-701.